Demand has surged for good manufacturing practice (GMP)–grade plasmid DNA (pDNA) used in late-phase clinical trials and commercial manufacturing due to the starting material’s critical role in producing nextgeneration therapies. The same is true for minicircle DNA (mcDNA) — supercoiled-DNA vectors that can be obtained from plasmids through cutting-edge in vivo recombination techniques. Because mcDNA lacks plasmid backbone sequences and contains primarily active genes, it can provide enhanced transgene expression with greater persistence than conventional plasmids can. Considering the biopharmaceutical industry’s great need for both pDNA and mcDNA, tools supporting fast-growing, high-yielding microbial cultures are becoming increasingly important.
Register or Login and hit Download to get the full article.